

STUDY**ROP-ET: Ropeginterferon alfa-2b for the treatment of ET with limited treatment options****Anticipated enrollment: N = 117****Primary endpoints:** Disease response at 12 months; peripheral blood count remission (PLTs $\leq 400 \times 10^9/L$ and WBC $< 10 \times 10^9/L$); hemorrhagic or thrombotic events; disease progression; and durable symptom improvement.**Eligibility:** Adult patients with ET who require cytoreductive treatment and have limited treatment options due to intolerance, resistance, or contraindications.**TRIAL DESIGN****Ropeginterferon alfa-2b | Every 2 weeks for up to 36 months****125 µg subcutaneous injections**Increase dosage up to 250 µg if optimal response is not achieved after 3 months.
Increase to 500 µg if optimal response is not achieved after 6 months.**12-month primary analysis period followed by up to 24 further months, to a maximum 36 months.****SCHEDULE OF ASSESSMENTS****Enrollment assessments:** Eligibility screen Informed consent Allocation

	BL	+2 wk	+4 wk	+6 wk	+8 wk	+3, 6, 9, 12, 18, 24, 30, 36 mo
Interventions						
Ropeg alfa-2b	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	
Assessments						
Medical history	<input checked="" type="checkbox"/>					
Hematology (PLT, WBC)	<input checked="" type="checkbox"/>			<input checked="" type="checkbox"/>		<input checked="" type="checkbox"/>
Disease-related signs and disease progression	<input checked="" type="checkbox"/>					<input checked="" type="checkbox"/> *
Questionnaires	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Blood tests	<input checked="" type="checkbox"/>					<input checked="" type="checkbox"/> †
Adverse events and other safety variables	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

*Except 3 months. †Except 3 months and 9 months.

The ROP-ET clinical trial aims to assess long-term clinical outcomes, as well as changes to allele burden, associated with the use of ropeg-alfa2b. The data produced from this trial may highlight an opportunity to advance the treatment landscape for patients with ET who have limited options due to intolerance, resistance, or contraindications.**Abbreviations:** BL, baseline; ET, essential thrombocythemia; mo, months; PLT, platelet count; WBC, white blood cells; wk, weeks.Kiladjian JJ, et al. *Ann Hematol.* 2024;103(7):2299-2310. doi: 10.1007/s00277-024-05665-4.**MPNHub**

Brought to you by

**SES**

This educational resource is supported through funds from pharmaceutical companies; a full list of our supporters can be found at mpn-hub.com. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.